Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 5/20 | 0.80 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL16762661 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3853 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6854301 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL107906 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL30987857 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6854302 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3852 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3299299 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL22077027 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6553361 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26793 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423298-B1 | — | — | None | — | — | US | claimed |
| WO-2026099512-A1 | MEDICAMENT DISPENSER DEVICE | PORTAL MEDICAL LIMITED (GB) | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | METOPI PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260077140-A1 | METERED DOSE INHALER FOR IPRATROPIUM BROMIDE SOLUTION | GLENMARK PHARMACEUTICALS LTD (IN) | 2026-03-19 | — | — | US | claimed |
| US-20260076900-A1 | IPRATROPIUM DELIVERY COMPOSITIONS, DEVICES AND METHODS | SOLSTICE ADVANCED MATERIALS US, INC. (US) | 2026-03-19 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| WO-1992000107-A1 | AEROSOL DRUG FORMULATIONS | GLAXO INC. (US) | 1992-01-09 | — | — | WO | claimed |
| WO-1992000062-A1 | THE USE OF SOLUBLE FLUOROSURFACTANTS FOR THE PREPARATION OF METERED-DOSE AEROSOL FORMULATIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-01-09 | — | — | WO | claimed |
| EP-0294940-B1 | PHARMACEUTICAL COMPOSITIONS | FISONS plc (GB) | 1991-12-11 | — | — | EP | claimed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | claimed |
| WO-1991011173-A1 | PROPELLANT COMPOSITIONS | FISONS PLC (GB) | 1991-08-08 | — | — | WO | claimed |
| EP-0239798-B1 | NEW PHARMACEUTICAL COMPOSITIONS FOR INHALATION | CHIESI FARMACEUTICI S.p.A. (IT) | 1990-09-26 | — | — | EP | claimed |
| WO-1990006775-A1 | A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS | LIPOSOME TECHNOLOGY, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| EP-0372777-A2 | Medicinal aerosol formulations | RIKER LABORATORIES, INC. (US) | 1990-06-13 | — | — | EP | claimed |
| EP-0294940-A1 | Pharmaceutical compositions | FISONS plc (GB) | 1988-12-14 | — | — | EP | claimed |
| EP-0239798-A1 | New pharmaceutical compositions for inhalation | CHIESI FARMACEUTICI S.p.A. (IT) | 1987-10-07 | — | — | EP | claimed |